WHO approves two new HPV vaccines, boosting global fight against cervical cancer
KARACHI: The World Health Organisation (WHO) has taken another step forward in the fight against cervical cancer by approving two new human papillomavirus (HPV) vaccines, Cecolin and Walrivax, for global marketing. This brings the total number of approved vaccines to five, increasing access to life-saving medications for girls in low- and middle-income countries.
WHO Director-General Dr Tedros Adhanom Ghebreyesus
emphasises that cervical cancer can be eliminated, and these new vaccine
approvals bring us closer to achieving that goal. Dr Kate O'Brien, Director of
the Department of Immunisation, Vaccines and Biologicals at WHO, notes that the
addition of Cecoline, a single-dose vaccine, will give countries more options
to reach more girls.
However, challenges remain, including global supply
shortages since 2018 and recent production challenges that have hindered HPV
vaccine introductions, potentially affecting millions of girls in Africa and
Asia. The WHO urges continued efforts to address these challenges and ensure
widespread access to these vaccines.
Key facts about cervical cancer and HPV vaccines:
- 95% of cervical cancer cases are caused by HPV, resulting in 660,000 new cases annually worldwide.
- 90% of cervical cancer deaths occur in low- and middle-income countries, with 19 of the 20 hardest-hit countries located in Africa.
- The WHO targets 90% of girls fully vaccinated with
HPV vaccine by age 15 as part of its global strategy for cervical cancer
elimination.
*With input from official sources.
--IV Desk https://indusvitals.blogspot.com/2024/09/sindh-moves-to-introduce-hpv-vaccine-to.html
Comments
Post a Comment